US · RARE · BIOTECHNOLOGY
Ultragenyx Pharmaceutical Inc. (RARE) intrinsic value and stock valuation
$16.48as of 2026-11-21 · Mkt cap 2.55B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Ultragenyx Pharmaceutical Inc. DCF and intrinsic value
InvestorsCraft values RARE with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from RARE’s statements →
Ultragenyx Pharmaceutical Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Apogee Therapeutics, Inc. (APGE) $135.07
- CG Oncology Inc. (CGON) $79.47
- Xenon Pharmaceuticals Inc. (XENE) $37.04
- Travere Therapeutics, Inc. (TVTX) $47.00
- Dyne Therapeutics, Inc. (DYN) $15.50
- Celcuity Inc. (CELC) $53.35
- IDEAYA Biosciences, Inc. (IDYA) $25.56
- Ascentage Pharma Group International (AAPG) $11.97
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $673M | $560.2M | $434.3M | $363.3M | $351.4M |
| Operating income | -$-535M | -$-535.97M | -$-569.21M | -$-648.92M | -$-381.74M |
| Net income | -$-575M | -$-569.18M | -$-606.64M | -$-707.42M | -$-454.02M |
| EPSd | -$-5.83M | -$-6.29M | -$-8.25M | -$-10.12M | -$-6.7M |
| Operating cash flow | -$-466M | -$-414.19M | -$-474.81M | -$-380.46M | -$-338.69M |
| Capital expenditure | -$-6M | -$-7.49M | -$-46.77M | -$-146.12M | -$-73.09M |
| Free cash flow | -$-472M | -$-421.68M | -$-521.57M | -$-526.59M | -$-411.79M |
| Total assets | $1.53B | $1.5B | $1.49B | $1.55B | $1.52B |
| Total debt | $1.28B | $40.3M | $43.2M | $31.6M | $42M |
| Net debt | $842M | -$-133.39M | -$-170.41M | -$-101.35M | -$-265.61M |
| Total equity | -$-73M | $262.3M | $275.4M | $352.5M | $922.6M |
| Cash and short-term investments | $693M | $610M | $577.2M | $747.8M | $740.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $673M | $560.2M | $434.3M | $363.3M | $351.4M |
| Cost of revenue | $109M | $76.7M | $45.2M | $28.3M | $16M |
| Gross profit | $564M | $483.5M | $389M | $335M | $335.4M |
| Research and development expenses | $750M | $697.9M | $648.5M | $705.8M | $497.2M |
| Selling, general and administrative expenses | $349M | $321.6M | $309.8M | $278.1M | $220M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $1.1B | $1.02B | $958.3M | $983.9M | $717.1M |
| Cost and expenses | $1.21B | $1.1B | $1B | $1.01B | $733.1M |
| Interest income | $25M | $36.5M | $26.7M | $11.1M | $1.93M |
| Interest expense | $62M | $63M | $66M | $43M | $29.4M |
| Depreciation and amortization | $35M | $35.5M | $26M | $18.2M | $13.2M |
| Ebitda | -$-474M | -$-469M | -$-516.45M | -$-640.49M | -$-410.32M |
| Operating income | -$-535M | -$-535.97M | -$-569.21M | -$-648.92M | -$-381.74M |
| Total other income/expenses, net | -$-36M | -$-31.61M | -$-39.26M | -$-52.81M | -$-71.24M |
| Income before tax | -$-571M | -$-567.59M | -$-608.46M | -$-701.73M | -$-452.98M |
| Income tax expense | $4M | $1.6M | -$-1.82M | $5.7M | $1.04M |
| Net income | -$-575M | -$-569.18M | -$-606.64M | -$-707.42M | -$-454.02M |
| Weighted average shares outstanding | $98.6M | $90.5M | $73.5M | $69.9M | $67.8M |
| Weighted average diluted shares outstanding | $98.6M | $90.5M | $73.5M | $69.9M | $67.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $693M | $610M | $577.2M | $747.8M | $740.2M |
| Net receivables | $159M | $121.8M | $73.4M | $40.5M | $44.4M |
| Inventory | $52M | $45M | $34M | $26.8M | $16.2M |
| Total current assets | $951M | $817.1M | $732.2M | $883.9M | $856.6M |
| Property, plant and equipment, net | $267M | $265.9M | $290.6M | $259.7M | $176.2M |
| Goodwill and intangible assets | $220M | $222.7M | $210.7M | $204.5M | $175.2M |
| Long-term investments | $59M | $135M | $199.9M | $149M | $293.9M |
| Total non-current assets | $581M | $686.3M | $758.8M | $661.5M | $665.8M |
| Total assets | $1.53B | $1.5B | $1.49B | $1.55B | $1.52B |
| Accounts payable | $31M | $38.8M | $42.1M | $43.3M | $17.1M |
| Short-term debt | $81M | $10.3M | $12.6M | $11.8M | $11.1M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $1.48M | $7.61M |
| Total current liabilities | $384M | $344.2M | $280.4M | $261.2M | $181.4M |
| Long-term debt | $1.2B | $30M | $30.6M | $19.8M | $30.9M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $1.47M |
| Total non-current liabilities | $1.22B | $897M | $935.2M | $931.7M | $418.5M |
| Capital lease obligations | $24M | $40.3M | $43.2M | $31.6M | $42M |
| Total liabilities | $1.61B | $1.24B | $1.22B | $1.19B | $599.8M |
| Common stock | $0.00 | $90K | $80K | $70K | $70K |
| Retained earnings | -$-4.53B | -$-3.96B | -$-3.39B | -$-2.78B | -$-2.07B |
| Accumulated other comprehensive income (loss) | $1M | -$-640K | $650K | -$-6.57M | -$-1.4M |
| Total equity | -$-73M | $262.3M | $275.4M | $352.5M | $922.6M |
| Total investments | $318M | $571.3M | $563.5M | $763.8M | $726.5M |
| Total debt | $1.28B | $40.3M | $43.2M | $31.6M | $42M |
| Net debt | $842M | -$-133.39M | -$-170.41M | -$-101.35M | -$-265.61M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-575M | -$-569.18M | -$-606.64M | -$-707.42M | -$-454.02M |
| Depreciation and amortization | $35M | $35.5M | $26M | $18.2M | $13.2M |
| Stock-based compensation | $153M | $158M | $135.2M | $130.4M | $105M |
| Change in working capital | -$-23M | $13.9M | -$-15.1M | $60.2M | -$-63.24M |
| Accounts receivable | -$-31M | -$-33.6M | -$-22.78M | -$-12.07M | -$-5.43M |
| Inventory | -$-6M | -$-11.21M | -$-6.93M | -$-9.7M | -$-3.12M |
| Accounts payable | $24M | $47M | $2.38M | $79.8M | $2.81M |
| Net cash provided by operating activities | -$-466M | -$-414.19M | -$-474.81M | -$-380.46M | -$-338.69M |
| Investments in property, plant and equipment | -$-6M | -$-7.49M | -$-44.27M | -$-116.12M | -$-73.09M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-75.03M | $0.00 |
| Net cash used for investing activities | $236M | -$-17.77M | $168M | -$-291.65M | -$-195.37M |
| Common stock issued | $86M | $381M | $379.8M | $0.00 | $78.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $478M | $399.2M | $388.1M | $501.2M | $118.6M |
| Net change in cash | $253.5M | -$-35.24M | $81.8M | -$-171.98M | -$-416.71M |
| Cash at end of period | $436M | $184.2M | $219.4M | $137.6M | $309.6M |
| Operating cash flow | -$-466M | -$-414.19M | -$-474.81M | -$-380.46M | -$-338.69M |
| Capital expenditure | -$-6M | -$-7.49M | -$-46.77M | -$-146.12M | -$-73.09M |
| Free cash flow | -$-472M | -$-421.68M | -$-521.57M | -$-526.59M | -$-411.79M |
Line items
Line items
Line items
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
- CEO
- Emil D. Kakkis
- Employees
- 1.37K
- Beta
- 0.31
Explore
Frequently asked questions
What is the intrinsic value of Ultragenyx Pharmaceutical Inc. (RARE)?
Ultragenyx Pharmaceutical Inc. (RARE) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is RARE undervalued?
RARE trades at a price of $16.48 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.